Literature DB >> 22561413

LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.

Raminder Aul1, Sheena Patel, Susan Summerhill, Iain Kilty, Jonathan Plumb, Dave Singh.   

Abstract

LPS inhalation was used to investigate whether sputum supernatant post-LPS challenge increases neutrophil chemotactic activity and to elucidate the role of CXCR1/CXCR2 signalling in this process. 14 healthy non-smoking subjects inhaled 30μg of LPS. Sputum was induced at baseline, 6 and 24h post-LPS challenge. Differential cell counts were determined and supernatants CXCL8, CXCL1, IL-6 and CCL2 levels measured. Peripheral blood neutrophils obtained from healthy volunteers were used for chemotaxis experiments using sputum supernatant. To delineate signalling mechanisms, the effects of a CXCR2/CXCR1 (dual) antagonist (Sch527123) and a CXCR2 specific antagonist (SB656933) were tested. LPS inhalation significantly increased sputum neutrophil counts from 45.3% to 76.7% and 69.3% at 6 and 24h respectively. LPS increased CXCL8, IL-6 and CCL2 levels but not CXCL1. Neutrophil chemotaxis significantly increased (2.7 fold) at 24h compared to baseline. Chemotaxis was inhibited by 79.0% with Sch527123 and 52.0% with SB656933. We conclude that LPS challenge increases sputum supernatant CXCL8 levels, which is associated with increased chemotactic activity which is dependent on both CXCR1 and CXCR2.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22561413     DOI: 10.1016/j.intimp.2012.04.008

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  12 in total

1.  Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949.

Authors:  Anna K Stalder; Dominik Lott; Daniel S Strasser; Hans G Cruz; Andreas Krause; Peter M A Groenen; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2016-11-15       Impact factor: 4.335

2.  Inflammation induced by inhaled lipopolysaccharide depends on particle size in healthy volunteers.

Authors:  Virginie Doyen; Gabrielle Pilcer; Phong Huy Duc Dinh; Francis Corazza; Alfred Bernard; Pierre Bergmann; Nicolas Lefevre; Karim Amighi; Olivier Michel
Journal:  Br J Clin Pharmacol       Date:  2016-07-28       Impact factor: 4.335

3.  A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling.

Authors:  Helen Ha; Tim Bensman; Henry Ho; Paul M Beringer; Nouri Neamati
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

4.  Characterization of the inflammatory response to inhaled lipopolysaccharide in mild to moderate chronic obstructive pulmonary disease.

Authors:  Vandana Gupta; Antonia Banyard; Aoibheann Mullan; Srividya Sriskantharajah; Thomas Southworth; Dave Singh
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

5.  Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability.

Authors:  Aaron D Schuler; Courtney A Engles; Dean Y Maeda; Mark T Quinn; Liliya N Kirpotina; Winston N Wicomb; S Nicholas Mason; Richard L Auten; John A Zebala
Journal:  Bioorg Med Chem Lett       Date:  2015-07-30       Impact factor: 2.823

6.  Effect of inhaled hydrosoluble curcumin on inflammatory markers in broncho-alveolar lavage fluid of horses with LPS-induced lung neutrophilia.

Authors:  Charlotte Sandersen; Dorothee Bienzle; Simona Cerri; Thierry Franck; Sandrine Derochette; Philippe Neven; Ange Mouytis-Mickalad; Didier Serteyn
Journal:  Multidiscip Respir Med       Date:  2015-04-15

7.  Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum.

Authors:  Arjun K Ravi; Shruti Khurana; Jonathan Lemon; Jonathan Plumb; George Booth; Louise Healy; Matthew Catley; Jørgen Vestbo; Dave Singh
Journal:  Respir Res       Date:  2014-09-04

8.  Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.

Authors:  Dean Y Maeda; Angela M Peck; Aaron D Schuler; Mark T Quinn; Liliya N Kirpotina; Winston N Wicomb; Guo-Huang Fan; John A Zebala
Journal:  J Med Chem       Date:  2014-10-08       Impact factor: 7.446

Review 9.  Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.

Authors:  Helen Ha; Bikash Debnath; Nouri Neamati
Journal:  Theranostics       Date:  2017-04-07       Impact factor: 11.556

10.  CXCR1-mediated neutrophil degranulation and fungal killing promote Candida clearance and host survival.

Authors:  Muthulekha Swamydas; Ji-Liang Gao; Timothy J Break; Melissa D Johnson; Martin Jaeger; Carlos A Rodriguez; Jean K Lim; Nathaniel M Green; Amanda L Collar; Brett G Fischer; Chyi-Chia Richard Lee; John R Perfect; Barbara D Alexander; Bart-Jan Kullberg; Mihai G Netea; Philip M Murphy; Michail S Lionakis
Journal:  Sci Transl Med       Date:  2016-01-20       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.